-
Low-level lead intoxication, known to adversely affect young children's cognitive development and behavior, may also harm young adults.
-
The FDA has approved tranexamic acid, an antifibrinolytic drug, for the treatment of cyclic heavy menstrual bleeding.
-
-
Losartan 150 mg/day reduced left ventricular ejection fraction, intolerance to ACE inhibitors, and the rate of death and/or hospital admission for heart failure in patients with CHF more than did losartan 50 mg/day, thereby demonstrating the potential value of uptitrating ARB doses to confer clinical benefit.
-
-
After 1 year, fewer than half of patients presenting with fatigue will have a diagnosis.
-
Fusobacterium necrophorum causes pharyngitis just as often as group A beta-hemolytic streptococcus in adolescents and young adults, and can result in the life-threatening Lemierre's syndrome. Macrolides should be avoided when this pathogen is suspected.
-
The FDA has approved capsaicin in a high-concentration, matrix-formulated dermal patch. It is designed to deliver a therapeutic dose into the skin during a 60-minute application. Capsaicin patch is marketed by NeurogesX, Inc., as Qutenza™
-
Based upon a presumed direct relationship with LDL lowering and reduction in CV events for persons with vasculopathy, many clinicians enthusiastically embraced the combination of ezetimibe with statins, especially when therapeutic LDL goals were difficult to attain with a statin alone.
-
Statin and niacin increase HDL-C, omeprazole reduces effectiveness of clopidogrel, darbe-poetin increases risk of stroke, statins decrease risk of gallstone disease, FDA Actions.
